Changes to Preferred Biosimilar Medications Effective October 1, 2026
MO HealthNet is changing preferred biosimilar medications effective October 1, 2026. Infliximab, Adalimumab, and Ustekinumab will have new preferred and non-preferred agent designations. Patients currently on non-preferred agents must switch to preferred versions unless an override is approved. Existing prior authorizations remain valid, but mandatory product switching will be enforced at the fiscal edit level.